Laboratory Medicine
Test Directory / Cyclosporin
Cyclosporin
EDTA
| Test | Cyclosporin |
|---|---|
| Common Abbreviations | CYC |
| Profile | NA |
| Tube type | EDTA |
| Clinical Indication | Used in the monitoring of immunosuppressant therapy. |
| Specimen Type | Blood |
| Sample type | EDTA whole blood |
| Minimum Volume | 0.5mL |
| Special Precautions | No special requirements |
| Stability | 5 days at 15 - 25°C or 7 days at 2 - 8°C or 6 months at -20°C |
| Turnaround Time | 4 days |
| Laboratory | York |
| Reference Interval | No firm therapeutic range exists for cyclosporine in whole blood. The complexity of the clinical state, individual differences in sensitivity to immunosuppressive and nephrotoxic effects of cyclosporine, coadministration of other immunosuppressants, type of transplant, time post-transplant, and a number of other factors contribute to different requirements for optimal blood levels of cyclosporine. Individual cyclosporine values cannot be used as the sole indicator for making changes in the treatment regimen. Each patient should be thoroughly evaluated clinically before treatment adjustments are made, and each assay user must establish his or her ranges based on clinical experience. |
| Limitations | Icteric or lipaemic samples should not be analysed. The assay is unaffected by biotin (< 123 nmol/L or < 30 ng/mL) Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration. In rare cases, interference due to extremely high titers of antibodies to analyte specific antibodies, streptavidin or ruthenium can occur. In vitro tests were performed by Roche on 16 commonly used pharmaceuticals. No interference with the assay was found. In addition, several special drugs were tested. No interference with the assay was found. |
| Notes |
